The latest fireworks over Mylan NV's price increases on EpiPen (epinephrine) could trigger more than just an investigation into the company's pricing practices. It could turn into a wider examination of industry's use of patient assistance programs (PAPs), which already are being probed by US federal prosecutors and state attorneys general.
Mylan's $600 price tag for the emergency treatment for allergic reactions, a 500% price increase since 2009, has captured widespread...